Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

May 31, 2007

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Celecoxib

Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.

DRUG

Creatine

10 g BID for either study arm

DRUG

Minocycline

Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm

Trial Locations (19)

10003

Beth Israel, New York

10032

Columbia University, New York

19107

University of Pennsylvania, Philadelphia

27705

Duke University, Durham

30912

Medical College of Georgia, Augusta

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic Rochester, Rochester

60637

University of Illinois, Chicago

63110

Washington University, St Louis

66160

University of Kansas, Kansas City

75390

UT Southwestern Medical Center, Dallas

85006

Phoenix Neurological Associates, Phoenix

87131

University of New Mexico, Albuquerque

90095

UCLA, Los Angeles

92868

University of California Irvine, Orange

94115

California Pacific Medical Center, San Francisco

97201

Oregon Health and Science University, Portland

08901

UMDNJ, New Brunswick

05405

University of Vermont, Burlington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ALS Association

OTHER

collaborator

Pfizer

INDUSTRY

lead

Columbia University

OTHER

NCT00355576 - Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter